Administration of Fibrinogen Concentrate for Refractory Bleeding

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Hematological PatientsBleedingPlatelet Refractoriness
Interventions
DRUG

Fibrinogen Concentrate Human

Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours. Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if \< 24 hours.

Trial Locations (1)

42055

RECRUITING

CHU de Saint-Etienne, Saint-Etienne

All Listed Sponsors
collaborator

Institut de Cancérologie de la Loire

OTHER

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER